• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. George Addresses Provider Issues Regarding Immunotherapies

Article

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer. He says that when the drug first came on the market many administrative challenges existed. There were limited access and associated reimbursement issues due to the limited production capabilities. However, Dr George states that currently there are no issues with payer coverage with little to no delays when it comes to prescribing the agent.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Screenshot of an interview with Nicolas Girard, MD, PhD
Byoung Chul Cho, MD, PhD
Efren Flores, MD
Emma Guttman-Yasskey, MD, PhD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.